Vimarsana
Biggest News Aggregation in the World

Nmda Receptor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nmda Receptor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nmda Receptor Today - Breaking & Trending Today

Interaction inhibitor blocks toxic effect of glutamate in ALS - Vimarsana News

Interaction inhibitor blocks toxic effect of glutamate in ALS

The discovery of a complex formed by two types of ion channels in neurons has allowed researchers from Heidelberg University to develop an inhibitor that stopped motor neuron degeneration in amyotrophic lateral sclerosis (ALS) in mouse models and human brain organoids.

Newco News: Arialys has autoimmune solution to psychosis problem - Vimarsana News

Newco News: Arialys has autoimmune solution to psychosis problem

Arialys Therapeutics Inc. launched this month with $58 million in seed funding, an experimental compound it is developing for autoimmune encephalitis and autoimmune psychosis, and high aspirations for its field. “Yes, I want to treat these patients, I want these patients to have a better life. But I also want drug discovery and development folks to think differently about discovering new drugs for the CNS,” Jay Lichter told BioWorld.

Brain protein deficiency promotes compulsive behaviour - Vimarsana News

Brain protein deficiency promotes compulsive behaviour

The absence of two proteins in mice, Intersectin1 and Intersectin2, leads to disrupted neural signalling and compulsive repetitive behaviour.

Detailed text transcripts for TV channel - CNN - 20190306:13:41:00 - Vimarsana News

Detailed text transcripts for TV channel - CNN - 20190306:13:41:00

Feeling of depression really go away. >> reporter: two years ago she heard about a clinical trial for a drug that's the chemical cousin of ketamine, perhaps best known as a club drug. over the last few years some doctors have been using it off label to treat the most stubborn cases of depression. now they have an fda approved drug to do the same. >> it's for about one third of people who don't seem to respond to the existing treatments. >> dr. manji is the head of neuroscience at janssen pharmaceuticals. >> all our previous anti-depressants work by serotonin or norepinephrine. this is complete...